Amal Therapeutics and the Oslo University Hospital announce research collaboration agreement for cancer immunotherapy validation
Geneva, Switzerland, September 8, 2015 – Amal Therapeutics, a Geneva based start-up Biotech Company developing and progressing therapeutic vaccines in oncology, announced today that it signed research collaboration agreement with the Oslo University Hospital (OUH)-Radiumhospitalet (Dept of Cellular Therapy). The objective of the collaboration is to validate Amal Therapeutics lead vaccine candidate using human-cells functional assay platform developed in the department.
View PDF
Amal Therapeutics to publish R&D findings in Cancer Research